Former commissioners continue push to move FDA out of HHS, but the alternative could create a different kind of political influence rather than eliminate it.
Former Commissioner Margaret Hamburg believes independence could free the US Food and Drug Administration of political influence and policymaking roadblocks, but the trade-offs that may be necessary could give many stakeholders pause.
Hamburg argued that an FDA outside the Health and Human Services Department could function similar to the Federal Trade Commission,...
Recent studies show that spaceflight can significantly weaken astronauts’ immune systems, making them more susceptible to infections and health complications during and after missions. Understanding these changes is crucial for ensuring the safety of future long-duration space travelers.
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
